GetTopicDetailResponse(id=1a02481899, topicName=Clazakizumab, introduction=Clazakizumab, content=null, image=null, comments=1, allHits=1103, url=https://h5.medsci.cn/topic?id=4818, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=34320, tagList=[TagDto(tagId=34320, tagName=Clazakizumab)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2005568, encodeId=34e52005568ee, content=<a href='/topic/show?id=1a02481899' target=_blank style='color:#2F92EE;'>#Clazakizumab#</a>, objectTitle=J Am Soc Nephrol：抗IL-6抗體clazakizumab對抗體介導(dǎo)的排斥反應(yīng)的有利作用, objectType=article, longId=205782, objectId=e8ea205e8249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8ea205e8249, replyNumber=0, likeNumber=115, createdTime=2021-05-23, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8ea205e8249, moduleTitle=J Am Soc Nephrol：抗IL-6抗體clazakizumab對抗體介導(dǎo)的排斥反應(yīng)的有利作用, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e8ea205e8249)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
